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In recent years, a companion diagnosis for prediction of
the effectiveness and the side effects after administration of
drugs has become very important to decide a therapeutic
strategy. In USA, Food and Drug Administration (FDA)
recommends the development of the companion diagnos-
tic agent simultaneously with a new drug development.
Nuclear medicine imaging using positron emission tomogra-
phy (PET) or single photon emission computed tomography
(SPECT), which visualizes target molecules, is able to detect
biological and biochemical changes in the earlier phases of
diseases differing from an anatomical imaging using X-ray
computed tomography (X-ray CT) or magnetic resonance
imaging (MRI). Radiolabeled tracers for the nuclearmedicine
have great potential to provide a lot of information about
pathology of individual patients depending on characteristics
of each tracer and could be the companion diagnostics.
Accordingly, molecular imaging and imaging-based therapy
using radiolabeled tracers must contribute to the realization
of personalized medicine.
11 selected papers are published in this special issue. Most
of them deal with important topics in nuclear medicine.
Below is a brief introduction to some of these papers in this
special issue.
In cerebral imaging, imaging of tau protein is useful for
presymptomatic diagnosis andmonitoring of the progression
of Alzheimer’s disease because the presence of neurofibrillary
tangles, composed of hyperphosphorylated tau protein, is
well correlated with neurodegeneration and cognitive decline
in Alzheimer’s disease. H. Watanabe et al. summarized tau
imaging probes for PET and SPECT.
In oncology, molecular targeted therapies using drugs,
such as tyrosine kinase inhibitors andmonoclonal antibodies,
become the mainstream in cancer therapy. It is important
to estimate the target molecule status in cancer tissues and
predict therapeutic efficacy. M. Yoshimoto et al. introduced
new radiolabeled tyrosine kinase inhibitors and antibodies
for theragnostic imaging and their clinical application in
molecular targeted therapy.
In the point of view from early detection of response to
therapy, apoptosis imaging could be useful because apoptosis
occur before anatomical change at posttreatment and could
contribute to personalized medicine. K. Ogawa and M. Aoki
introduced radiolabeled compounds for molecular imaging
of apoptosis (cell death), their applications, and utility in
medicine.
Hypoxic regions in tumors are known to be resistant to
chemotherapy and radiotherapy. Hypoxia-inducible factor-1
(HIF-1) expressed in hypoxic regions regulates expression of
genes related to tumor growth, angiogenesis, metastasis, and
therapy resistance. Thus, imaging of HIF-1-active regions in
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tumors is of great interest. M. Ueda and H. Saji summarized
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